{"id":97,"date":"2011-01-30T03:22:26","date_gmt":"2011-01-30T03:22:26","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/"},"modified":"2026-02-22T00:42:23","modified_gmt":"2026-02-22T00:42:23","slug":"cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/","title":{"rendered":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith)"},"content":{"rendered":"<p>Neurofibromatosis type 2 (NF2) is caused by mutations in the <em>NF2<\/em> gene. Around half of NF2 patients in various studies have been shown to have meningiomas, although the factors determining which individuals will develop meningiomas are unclear. We analysed the correlation between incidence of cranial meningiomas and mutation position within the <em>NF2<\/em> gene in 411 NF2 patients.<\/p>\n<p>We found a clear effect of mutation position with risk of meningioma and no overall difference in risk between men and women, although men had a slightly increased risk below age 20. This information is of value when counselling patients about their risk of cranial meningioma. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2011\/01\/28\/jmg.2010.085241?papetoc\">http:\/\/jmg.bmj.com\/content\/early\/2011\/01\/28\/jmg.2010.085241?papetoc<\/a>=)<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene. Around half of NF2 patients in various studies have been shown to have meningiomas, although the factors determining which individuals will develop meningiomas are unclear. We analysed the correlation between incidence of cranial meningiomas and mutation position within the NF2 gene in 411 [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-97","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene. Around half of NF2 patients in various studies have been shown to have meningiomas, although the factors determining which individuals will develop meningiomas are unclear. We analysed the correlation between incidence of cranial meningiomas and mutation position within the NF2 gene in 411 [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2011-01-30T03:22:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-22T00:42:23+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith)\",\"datePublished\":\"2011-01-30T03:22:26+00:00\",\"dateModified\":\"2026-02-22T00:42:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/\"},\"wordCount\":140,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/\",\"name\":\"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2011-01-30T03:22:26+00:00\",\"dateModified\":\"2026-02-22T00:42:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2011\\\/01\\\/30\\\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/","og_locale":"en_US","og_type":"article","og_title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog","og_description":"Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene. Around half of NF2 patients in various studies have been shown to have meningiomas, although the factors determining which individuals will develop meningiomas are unclear. We analysed the correlation between incidence of cranial meningiomas and mutation position within the NF2 gene in 411 [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/","og_site_name":"JMG Contact blog","article_published_time":"2011-01-30T03:22:26+00:00","article_modified_time":"2026-02-22T00:42:23+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith)","datePublished":"2011-01-30T03:22:26+00:00","dateModified":"2026-02-22T00:42:23+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/"},"wordCount":140,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/","url":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/","name":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2011-01-30T03:22:26+00:00","dateModified":"2026-02-22T00:42:23+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2011\/01\/30\/cranial-meningiomas-in-411-neurofibromatosis-type-2-nf2-patients-with-proven-gene-mutations-clear-positional-effect-of-mutations-but-absence-of-female-severity-effect-on-age-at-onset\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset (Contributed by Dr. Miriam J Smith)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/97","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=97"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/97\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=97"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=97"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=97"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}